Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2007

View Archived Issues

Takeda looks back on FY2006

Positive preclinical results with combined anthrax and plague vaccine

Clinical studies of drugs for digestive diseases

New therapeutic options for cancer imparted in recent patents

Recent Schering and Vertex patents describe novel therapeutic agents for respiratory disorders

Recent GSK patent discloses novel agents targeting hepatitis C virus infection

Clinical data on lisdexamfetamine in ADHD detailed

Pooled data show efficacy and safety of agomelatine in major depressive disorder

Recent clinical trials in urological cancer

LCP-Tacro delivers higher bioavailability compared to Prograf

First-in-class GABA-enhanced antipsychotic safe and well-tolerated in phase I study

Improved efficacy of PhGalpha1 demonstrated in new preclinical studies

NICE recommends use of Champix on U.K.'s National Health Service

Orlistat GSK recommended for approval in E.U.

XMT-1001 begins phase I study in solid tumors

Novacea and Schering-Plough sign license agreement for Asentar

CeNeRx licenses rights to PharmaNess cannabinoid portfolio

LymphoStat-B begins second phase III trial for SLE

XL-647 studied in new phase II NSCLC trial

Canadian approval for Thelin

Vernakalant (iv) filed in Canada

Aeras Global TB Vaccine Foundation updates TB vaccine development progress

Twice-daily Zyflo CR receives FDA approval

Vantas progresses through E.U. mutual recognition procedure

FDA approves new formulation of FazaClo

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...